• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    AnaptysBio upgraded by H.C. Wainwright with a new price target

    6/4/25 7:31:04 AM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    H.C. Wainwright upgraded AnaptysBio from Neutral to Buy and set a new price target of $38.00
    Get the next $ANAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    6/4/2025$38.00Neutral → Buy
    H.C. Wainwright
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    4/16/2024$47.00Outperform
    Leerink Partners
    4/11/2024$56.00Overweight
    Wells Fargo
    More analyst ratings